Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer

被引：7

作者：

Telli, Melinda L. ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 29期

关键词：

III RANDOMIZED GEPARTRIO; PREOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; TRASTUZUMAB; THERAPY; TRIAL; CYCLOPHOSPHAMIDE; PACLITAXEL; EPIRUBICIN;

D O I：

10.1200/JCO.2013.51.0313

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3613 / 3615

页数：3

共 17 条

[1] Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen [J].

Buzdar, Aman U. ;

Valero, Vicente ;

Ibrahim, Nuhad K. ;

Francis, Deborah ;

Broglio, Kristine R. ;

Theriault, Richard L. ;

Pusztai, Lajos ;

Green, Marjorie C. ;

Singletary, Sonja E. ;

Hunt, Kelly K. ;

Sahin, Aysegul A. ;

Esteva, Francisco ;

Symmans, William F. ;

Ewer, Michael S. ;

Buchholz, Thomas A. ;

Hortobagyi, Gabriel N. .

CLINICAL CANCER RESEARCH, 2007, 13 (01) :228-233

[2] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[3] Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) [J].

Cortazar, P. ;

Zhang, L. ;

Untch, M. ;

Mehta, K. ;

Costantino, J. ;

Wolmark, N. ;

Bonnefoi, H. ;

Cameron, D. ;

Gianni, L. ;

Valagussa, P. ;

Zujewski, J. A. ;

Justice, R. ;

Loibl, S. ;

Wickerham, L. ;

Bogaerts, J. ;

Baselga, J. ;

Perou, C. ;

Blumenthal, G. ;

Blohmer, J. ;

Mamounas, E. ;

Bergh, J. ;

Semiglazov, V. ;

Prowell, T. ;

Eidtmann, H. ;

Paik, S. ;

Piccart, M. ;

Sridhara, R. ;

Fasching, P. ;

Swain, S. M. ;

Slaets, L. ;

Tang, S. ;

Gerber, B. ;

Geyer, C. ;

Pazdur, R. ;

Ditsch, N. ;

Rastogi, P. ;

Eiermann, W. ;

von Mincwitz, G. .

CANCER RESEARCH, 2012, 72

[4] Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].

Fisher, B ;

Bryant, J ;

Wolmark, N ;

Mamounas, E ;

Brown, A ;

Fisher, ER ;

Wickerham, DL ;

Begovic, M ;

DeCillis, A ;

Robidoux, A ;

Margolese, RG ;

Cruz, AB ;

Hoehn, JL ;

Lees, AW ;

Dimitrov, NV ;

Bear, HD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685

[5] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Manikhas, Alexey ;

Lluch, Ana ;

Tjulandin, Sergey ;

Zambetti, Milvia ;

Vazquez, Federico ;

Byakhow, Mikhail ;

Lichinitser, Mikhail ;

Angel Climent, Miguel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Baronio, Roberta ;

Feyereislova, Andrea ;

Barton, Claire ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET, 2010, 375 (9712) :377-384

[6]

Kim MS., Ann Oncol

[7] Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].

Liedtke, Cornelia ;

Mazouni, Chafika ;

Hess, Kenneth R. ;

Andre, Fabrice ;

Tordai, Attila ;

Mejia, Jaime A. ;

Symmans, W. Fraser ;

Gonzalez-Angulo, Ana M. ;

Hennessy, Bryan ;

Green, Marjorie ;

Cristofanilli, Massimo ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1275-1281

[8] Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis [J].

Mauri, D ;

Pavlidis, N ;

Ioannidis, JPA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03) :188-194

[9] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[10] Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J].

Rastogi, Priya ;

Anderson, Stewart J. ;

Bear, Harry D. ;

Geyer, Charles E. ;

Kahlenberg, Morton S. ;

Robidoux, Andre ;

Margolese, Richard G. ;

Hoehn, James L. ;

Vogel, Victor G. ;

Dakhil, Shaker R. ;

Tamkus, Deimante ;

King, Karen M. ;

Pajon, Eduardo R. ;

Wright, Mary Johanna ;

Robert, Jean ;

Paik, Soonmyung ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :778-785

← 1 2 →